EcoDrugPlus

Proteasome 20s Subunit Beta 9

Ensembl ID : ENSBBBG00000003777
Gene Symbol: PSMB9
3 Cross references
214 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSBBBG00000015048
Gene Symbol: PSMD2
3 Cross references
224 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4

Ensembl ID : ENSBBBG00000002695
Gene Symbol: PSMD4
3 Cross references
287 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1

Ensembl ID : ENSBBBG00000018666
Gene Symbol: PSMC1
3 Cross references
316 Possible Orthologues:

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSBBBG00000012942
Gene Symbol: PSMC2
3 Cross references
228 Possible Orthologues:

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSBBBG00000002347
Gene Symbol: PSMC3
3 Cross references
228 Possible Orthologues:

Proteasome 26s Subunit, Atpase 4

Ensembl ID : ENSBBBG00000004477
Gene Symbol: PSMC4
3 Cross references
199 Possible Orthologues:

Proteasome 26s Subunit, Atpase 5

Ensembl ID : ENSBBBG00000014258
Gene Symbol: PSMC5
3 Cross references
226 Possible Orthologues:

Proteasome 26s Subunit, Atpase 6

Ensembl ID : ENSBBBG00000006636
Gene Symbol: PSMC6
3 Cross references
236 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 1

Ensembl ID : ENSBBBG00000025188
Gene Symbol: PSMD1
3 Cross references
211 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 11

Ensembl ID : ENSBBBG00000015842
Gene Symbol: PSMD11
3 Cross references
283 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 12

Ensembl ID : ENSBBBG00000014773
Gene Symbol: PSMD12
3 Cross references
222 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).